OR WAIT null SECS
January 05, 2022
FDA maintained a steady pace in 2021 in approving important new therapies for market, including new vaccines and treatments for COVID-19.
January 04, 2022
Thermo Fisher Scientific’s Invitrogen TrueCut HiFi Cas9 Protein offers the advantage of significantly minimizing off-target events while aiming to retain maximum on-target editing efficiency.
The partnership between OpenEye Scientific and Specifica has generated AbXtract, an antibody discovery model that is included in the Orion Antibody Suite.
January 03, 2022
The agency is expanding the use of a single booster of the Pfizer-BioNTech vaccine to children ages 12–15 and is shortening the time between primary vaccination and booster to at least five months.
FDA authorized emergency use of Pfizer’s oral antiviral drug to make the drug available as quickly as possible.
An obvious theme for 2021 has been COVID-19, but the next 12 months will see industry and its people experiencing further change.
January 02, 2022
Overall, 2021 proved to be another good year for drug approvals in Europe, albeit with a slight disappointment for Alzheimer’s patients, but what should industry be watching out for in 2022?
December 23, 2021
Moderna’s vaccine is weaker against the Omicron variant, but boosters can increase neutralizing antibody levels by as much as 83-fold.
Sanofi’s acquisition of Amunix will grant access to their promising immuno-oncology pipeline.
December 22, 2021
Tezpire (tezepelumab-ckko) has been approved as an add-on maintenance treatment for severe asthma.